8-K: Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results; Withdraws Full Year Guidance Amid Acquisition

Walgreens Boots Alliance (WBA) reported its fiscal 2025 second quarter results, showing a loss per share of $3.30, sales of $38.6 billion, and announced the withdrawal of its fiscal 2025 guidance due to a pending acquisition by Sycamore Partners.

Summary

• Walgreens Boots Alliance (WBA) announced its financial results for the second quarter of fiscal year 2025, which ended on February 28, 2025.
• The company reported a loss per share of $3.30, compared to a loss per share of $6.85 in the same quarter of the previous year.
• Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities.
• Adjusted earnings per share (EPS) was $0.63, a decrease from $1.20 in the year-ago quarter.
• The decline in adjusted EPS was primarily driven by prior year adjusted effective tax benefit, lower U.S. retail sales and prior year sale-leaseback gains, partly offset by cost savings within U.S. Retail Pharmacy and growth in U.S. Healthcare.
• Second quarter sales increased by 4.1 percent year-over-year to $38.6 billion, or 4.7 percent on a constant currency basis.
• Given the pending transaction for WBA to be acquired by entities affiliated with Sycamore Partners, the company is withdrawing its fiscal 2025 guidance.
• Sales in the first six months of fiscal 2025 increased 5.8 percent from the year-ago period to $78.0 billion, an increase of 5.8 percent on a constant currency basis, reflecting sales growth across all business segments.
• Net loss for the first six months of fiscal 2025 was $3.1 billion, a decrease of 47.8 percent compared to a net loss of $6.0 billion in the year-ago period, reflecting non-cash impairment charges partly offset by $1.0 billion in after-tax gains on early settlement of variable prepaid forward derivatives related to the monetization of Cencora shares and gains on investments in BrightSpring.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While sales increased, earnings declined and the withdrawal of guidance due to the pending acquisition introduces uncertainty. The company is also facing significant impairment charges and legal settlements.

Positives

• Second quarter sales increased 4.1 percent year-over-year to $38.6 billion.
• Net loss decreased 51.7 percent compared to the year-ago quarter.
• Net cash used for operating activities improved by $438 million compared with the year-ago quarter.
• Free cash flow improved by $192 million compared with the year-ago quarter.
• U.S. Retail Pharmacy segment sales increased 5.3 percent from the year-ago quarter.
• Comparable sales increased 8.2 percent from the year-ago quarter.
• Boots UK comparable retail sales increased 5.1 percent on a constant currency basis.
• Boots.com sales grew 19.5 percent, or 20.4 percent on a constant currency basis.
• Adjusted EBITDA of $158 million improved by $140 million versus the prior year quarter, reflecting improvement at VillageMD and growth at Shields.

Negatives

• Second quarter loss per share was $3.30.
• Adjusted earnings per share (EPS) was $0.63 compared to adjusted EPS of $1.20 in the year-ago quarter.
• Operating loss in the second quarter was $5.6 billion.
• Free cash flow was negative $418 million.
• Retail sales decreased 5.5 percent and comparable retail sales decreased 2.8 percent from the year-ago quarter, driven by lower sales in discretionary categories including beauty, seasonal and general merchandise.
• Adjusted operating income decreased 4.7 percent to $234 million, a decrease of 2.5 percent on a constant currency basis compared with the year-ago quarter, reflecting cost inflation primarily driven by payroll, along with technology investments.
• VillageMD sales decreased 6.2 percent.

Risks

• The company is withdrawing fiscal 2025 guidance due to the pending acquisition, creating uncertainty about future financial performance.
• The pending acquisition is subject to shareholder and regulatory approvals, and other conditions to closing, which may not be satisfied.
• The company faces risks related to the announcement and completion of the proposed merger, including potential impacts on business relationships, operating results, and the ability to retain key personnel.
• The company is exposed to risks related to litigation and opioid-related settlements.
• The company faces risks related to adverse global macroeconomic conditions, including inflation, high interest rates, labor shortages, and supply chain disruptions.
• The company faces risks related to the financial performance of its equity method investments, including Cencora.
• The company faces risks related to the expansion and future operating and financial results of its U.S. Healthcare segment, including its long-term sales targets and profitability expectations.

Future Outlook

Given the pending transaction, pursuant to which WBA will be acquired by entities affiliated with Sycamore Partners, the company is withdrawing fiscal 2025 guidance.

Management Comments

• Chief Executive Officer Tim Wentworth said: Second quarter results reflect disciplined cost management and improvement in U.S. Healthcare, which were partially offset by weaker front-end results in U.S. Retail Pharmacy, while significant legal settlements resulted in continued negative free cash flow.
• We remain in the early stages of our turnaround plan, and continue to expect that meaningful value creation will take time, enhanced focus and balancing future cash needs with necessary investments to navigate a changing pharmacy and retail landscape.

Industry Context

The announcement comes at a time when the retail pharmacy industry is facing challenges such as changing reimbursement models, increased competition, and evolving consumer preferences. WBA's strategic review and potential acquisition reflect efforts to adapt to these industry dynamics.

Comparison to Industry Standards

• CVS Health, a major competitor, has been focusing on expanding its healthcare services and digital capabilities.
• WBA's performance can be compared to that of Rite Aid, which has been facing financial difficulties and restructuring efforts.
• The withdrawal of guidance due to the pending acquisition is a common practice in such situations, as it reflects the uncertainty surrounding the company's future direction.
• The impairment charges related to VillageMD highlight the challenges in the healthcare services sector, where companies are facing pressure to improve profitability and demonstrate value.

Stakeholder Impact

• Shareholders face uncertainty due to the pending acquisition and withdrawal of guidance.
• Employees may experience changes related to the acquisition and restructuring efforts.
• Customers may see changes in services and offerings as the company adapts to the changing retail and healthcare landscape.
• Suppliers and creditors may be affected by the acquisition and any resulting changes in business strategy.

Next Steps

• The merger is expected to close in the fourth quarter of calendar year 2025, pending shareholder and regulatory approvals and other conditions to closing.
• WBA common stock will no longer be listed on the Nasdaq Stock Market upon completion of the transaction, and WBA will become a private company.
• The company expects to file its Quarterly Report on Form 10-Q for the quarter ended February 28, 2025, with the Securities and Exchange Commission (the SEC).

Key Dates

Keywords

Walgreens Boots Alliance, Financial Results, Second Quarter, Fiscal 2025, Acquisition, Sycamore Partners, Retail Pharmacy, U.S. Healthcare, Sales, EPS, Guidance, Impairment Charges, Legal Settlements